Here, we examined the expression of a potential glioma biomarker, MDGI (Hyvönen et al, 2014), in WHO grade II–III glioma and glioblastoma (grade IV) specimens, publicly available datasets as well as in patient‐derived and commercially available glioblastoma cell lines. This evidence concerns the gene FABP3 and central nervous system cancer.